All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What does the future hold for patients with relapsed AML?

During the 4th National Cancer Research Institute (NCRI) AML Academy Meeting, the AML Hub was pleased to speak to Pramila Krishnamurthy, King’s College Hospital NHS Foundation Trust, London, UK. We asked, What does the future hold for patients with relapsed acute myeloid leukemia (AML)?

What does the future hold for patients with relapsed AML?

Krishnamurthy discusses the changing landscape of frontline therapy and challenges facing clinicians. Focusing on topics such as the use of novel doublet and triplet combination agents, menin inhibitors, and the potential of immune and CAR T-cell therapies, Krishnamurthy presents her thoughts on what the future holds for patients with relapsed AML, including the importance of clinical trials specifically for this subgroup.


Subscribe to get the best content related to AML delivered to your inbox